ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,555
-0,17%
Bitcoin
65 171,49
0,31%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. INmune Bio Inc (INMB)

  7. INmune Bio Inc (INMB) Actualités

INMB INmune Bio Inc

7,70
-0,58 (-7,00%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
INmune Bio Inc INMB NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,58 -7,00% 7,70 01:48:39
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
8,23 7,41 8,4099 7,70 8,28
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
13/6/202422:05EDGAR2Form 8-K - Current report
12/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202422:00EDGAR2Form 8-K - Current report
30/5/202414:00GLOBEINmune Bio Inc. to Join Russell 3000® Index
29/5/202422:05EDGAR2Form DEF 14A - Other definitive proxy statements
23/5/202422:00EDGAR2Form 8-K - Current report
16/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:00EDGAR2Form 8-K - Current report
09/5/202422:05GLOBEINmune Bio Inc. Announces First Quarter 2024 Results and..
07/5/202414:00GLOBEINmune Bio Inc. to Report First Quarter 2024 Financial..
30/4/202414:00GLOBEINmune Bio Inc. Provides Update on Two Patients from the..
29/4/202414:00GLOBEINmune Bio Inc. Completes First Cohort and Initiates Second..
25/4/202415:00GLOBEINmune Bio Inc. Announces $9.7 Million Registered Direct..
23/4/202414:00GLOBEINmune Bio Inc. Announces 24-Month Stability Validation of..
22/4/202414:00GLOBEINmune Bio Inc. Raises Approximately $4.8 Million in Gross..
08/4/202414:00GLOBEINmune Bio Inc. Presents Data on INB03’s Role as an Immune..
28/3/202421:01GLOBEINmune Bio Inc. Announces Year End 2023 Results and Provides..
26/3/202421:01GLOBEINmune Bio Inc. to Report Fourth Quarter 2023 Financial..
13/3/202413:00GLOBEINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives..
05/3/202414:00GLOBEINmune Bio Reports Significant EEG Improvement in..
12/2/202415:00GLOBEINmune Bio to Participate in the Oppenheimer 34th Annual..
06/2/202415:00GLOBEINmune Bio to Participate in Baird’s Biotech Discovery..
30/1/202414:02EDGAR2Form 8-K - Current report
30/1/202414:00GLOBEINmune Bio Announces FDA Removal of Clinical Hold for..
16/1/202414:30GLOBEELEVAI Labs, Inc. Acquires Worldwide License Agreement for..
02/1/202422:00EDGAR2Form 8-K - Current report
02/1/202414:00GLOBEINmune Bio Announces First Patient Dosed in a Phase 1/2..
18/12/202322:15EDGAR2Form 8-K - Current report
18/12/202322:05EDGAR2Form 8-A12B/A - Registration of securities [Section 12(b)]:..
18/12/202322:01EDGAR2Form 8-K - Current report
18/12/202322:01GLOBEINmune Bio Provides Update Regarding Global Alzheimer’s..
29/11/202322:00EDGAR2Form 8-K - Current report
29/11/202314:00GLOBEINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake..
27/11/202322:00EDGAR2Form 8-K - Current report
27/11/202314:00GLOBEINmune Bio Receives EMA’s Authorization in France and Spain..
15/11/202322:13EDGAR2Form 8-K - Current report
15/11/202315:00GLOBEINmune Bio Inc. Announces Expansion of Phase II Clinical..
13/11/202317:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:13EDGAR2Form 8-K - Current report
01/11/202321:10GLOBEINmune Bio Inc. Announces Third Quarter 2023 Results and..
01/11/202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202321:25EDGAR2Form 8-K - Current report
31/10/202313:00GLOBEINmune Bio Inc. Patent Claims Covering INB16 Cell Line and..
30/10/202314:07GLOBEINmune Bio Inc. Presents Preclinical Data at SITC 2023..
17/10/202314:00GLOBEINmune Bio Inc. Presents New Biomarker and Feasibility Data..
16/10/202315:00GLOBEINmune Bio Inc. to Report Third Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
INMB
INmune Bio
BIT
P1U3O2
NLBNPIT1U3O2 20240621 32
TSXV
WHD
TG
WMT
Walmart
BIT
FCM
Friulchem
LSE
SX78
Newday Fmi 30 A
BIT
SCK
Sciuker Frames
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés